NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.41 (-0.51%) GOLD FUTURES
2,430.30 +12.90 (+0.53%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,401.39 +2,350.59 (+4.52%)
VBIV May 2024 5.000 put
| Previous close | 4.3800 |
| Open | N/A |
| Bid | 4.0000 |
| Ask | 5.0000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 4.3800 - 4.3800 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireVBI Vaccines Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 15, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2024.
Business WireVBI Vaccines Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., April 16, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
Business WireVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass., April 11, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,272,728 of its common shares and warrants to purchase up to 2,272,728 common shares, at an offering price of $0.88 per common share and associated warrant. The warrants have an exercise
